

Complete Nucleotide Sequences of *bla*_{KPC-4}- and *bla*_{KPC-5}-Harboring IncN and IncX Plasmids from *Klebsiella pneumoniae* Strains Isolated in New Jersey

Liang Chen,^a Kalyan D. Chavda,^a Henry S. Fraimow,^b José R. Mediavilla,^a Roberto G. Melano,^{c,d,e} Michael R. Jacobs,^f Robert A. Bonomo,^{g,h} Barry N. Kreiswirth^a

Public Health Research Institute Center, International Center for Public Health, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA^a; Division of Infectious Diseases, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey, USA^b; Ontario Agency for Health Protection and Promotion, Toronto, Ontario, Canada^c; University of Toronto, Toronto, Ontario, Canada^d; Mount Sinai Hospital, Toronto, Ontario, Canada^e; Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio, USA^f; Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA^g; Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA^h

Klebsiella pneumoniae carbapenemase (KPC)-producing *Enterobacteriaceae* have emerged as major nosocomial pathogens. *bla*_{KPC}, commonly located on Tn4401, is found in Gram-negative bacterial strains, with the two most common variants, *bla*_{KPC-2} and *bla*_{KPC-3}, identified in plasmids with diverse genetic backgrounds. In this study, we examined *bla*_{KPC-4}- and *bla*_{KPC-5}-bearing plasmids recovered from two *K. pneumoniae* strains, which were isolated from a single New Jersey hospital in 2005 and 2006, respectively. IncN plasmid pBK31551 is 84 kb in length and harbors *bla*_{KPC-4}, *bla*_{TEM-1}, *qnrB2*, *aac(3)-Ib*, *aph(3')-I*, *qacF*, *qacEΔ1*, *sull1*, and *dfrA14*, which confer resistance to β-lactams, quinolones, aminoglycosides, quaternary ammonium compounds, and co-trimoxazole. The conserved regions within pBK31551 are similar to those of other IncN plasmids. Surprisingly, analysis of the Tn4401 sequence revealed a large IS110- and Tn6901-carrying element (8.3 kb) inserted into the *istA* gene, encoding glyoxalase/bleomycin resistance, alcohol dehydrogenase, and S-formylglutathione hydrolase. Plasmid pBK31567 is 47 kb in length and harbors *bla*_{KPC-5}, *dfrA5*, *qacEΔ1*, and *sull1*. pBK31567 belongs to a novel IncX subgroup (IncX5) and possesses a highly syntenic plasmid backbone like other IncX plasmids; however, sequence similarity at the nucleotide level is divergent. The *bla*_{KPC-5} gene is carried on a Tn4401 element and differs from the genetic environment of *bla*_{KPC-5} described in *Pseudomonas aeruginosa* strain P28 from Puerto Rico. This study underscores the genetic diversity of multidrug-resistant plasmids involved in the spread of *bla*_{KPC} genes and highlights the mobility and plasticity of Tn4401. Comparative genomic analysis provides new insights into the evolution and dissemination of KPC plasmids belonging to different incompatibility groups.

Carbapenem-resistant *Enterobacteriaceae* (CRE) have emerged as a major cause of nosocomial infections worldwide. The therapeutic challenges associated with these highly resistant strains correlate with higher morbidity and mortality, increased length of hospitalization, and an overall increase in health care costs (1). In the past decade, the spread of *Klebsiella pneumoniae* carbapenemase (KPC), a class A serine β-lactamase, has led to a rapid rise in prevalence of CRE infections in the United States and other global regions (2). Currently, 12 KPC variants (KPC-2 to KPC-13) have been identified since the initial report, with KPC-2 and KPC-3 identified as the most frequent types and *K. pneumoniae* as the most common host species (2, 3). Genotypic studies of emerging KPC-bearing *K. pneumoniae* strains from international sources indicate that the predominant strains are typically multilocus sequence type 258 (ST258), which is suggestive of pandemic spread by a single clone (2, 4–7).

KPC is encoded by the *bla*_{KPC} gene, which is carried by Tn4401 or Tn4401-like genetic elements, and has been reported in a variety of transferable plasmids (8–14). Tn4401 is approximately 10 kb in size, is delimited by two 39-bp imperfect inverted repeats, and harbors insertion sequences ISKpn6 and ISKpn7 in addition to transposase and resolvase genes (15). Tn4401 and *bla*_{KPC} genes have been reported in plasmids of various sizes, which differ in their ability to transfer within and between species, harbor different antibiotic resistance elements, and possess different incom-

patibility (Inc) groups, including IncFII, IncL/M, IncN, IncR, and ColE1 (4, 6, 10, 16).

Whole-plasmid sequencing and comparative genomic analyses have identified common functional modules and unique acquired genes that provide important molecular information for developing epidemiological tools to identify and track the spread of resistance plasmids within and among *Enterobacteriaceae* species (17–20). Various *bla*_{KPC-2}- and *bla*_{KPC-3}-harboring plasmids belonging to different Inc groups have been successfully sequenced, including IncN plasmids p9 and p12 (10), IncFII plasmids pKPHS2 (21), pKP048 (19), pKpQIL (20), pKpQIL-IT (18), and pSLMT (HQ589350), and ColE1 plasmid p15S (10). However, the complete sequence analysis of carbapenem resistance plasmids belonging to other Inc groups, or harboring other *bla*_{KPC} variants, has not been described. Here we report the complete sequences of two plasmid genomes harboring *bla*_{KPC-4} and *bla*_{KPC-5}, recovered

Received 9 August 2012 Returned for modification 6 October 2012

Accepted 19 October 2012

Published ahead of print 31 October 2012

Address correspondence to Barry N. Kreiswirth, kreiswba@umdnj.edu.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.01648-12

from two *K. pneumoniae* isolates cultured at the same New Jersey hospital. Our analysis shows the genetic diversity of multidrug-resistant plasmids involved in the spread of the *bla*_{KPC} genes and highlights the mobility and plasticity of Tn4401.

(This study was partially presented at the 52nd Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy [ICAAC], 2012.)

MATERIALS AND METHODS

Retrospective analysis of carbapenem-resistant *K. pneumoniae*. A total of 27 carbapenem-resistant *K. pneumoniae* strains isolated from 2005 to 2010 at a single New Jersey hospital were genetically characterized. Detection of *bla*_{KPC} genes and identification of the epidemic *K. pneumoniae* ST258 clone were performed using multiplex real-time PCR methods described previously (22, 23), and full-length *bla*_{KPC} genes were characterized by conventional PCR and DNA sequencing (24). Two KPC-4-harboring strains were detected: BK31551 (CK7) and BK31572 (CK180) were isolated from blood culture samples from two patients with bacteremia in September 2005 and November 2006, respectively. KPC-5-bearing strain BK31567 (CK102) was isolated from a blood culture sample from a patient with urosperis in April 2006.

Species were identified using the Vitek 2 system (bioMérieux), and MICs were determined by broth microdilution in cation-adjusted Mueller-Hinton broth (MHB) according to Clinical and Laboratory Standards Institute methods (25), using Sensititre GNX2F trays (Thermo Fisher Scientific, Waltham, MA). Carbapenem resistance was defined by MICs of higher than the 2012 CLSI breakpoints for one or more of the following carbapenem agents: imipenem, ≥ 4 $\mu\text{g/ml}$; meropenem, ≥ 4 $\mu\text{g/ml}$; ertapenem, ≥ 2 $\mu\text{g/ml}$; and doripenem, ≥ 4 $\mu\text{g/ml}$ (25).

Characterization of *bla*_{KPC-4}⁻ and *bla*_{KPC-5}⁻-harboring plasmids and strains. Plasmid DNA was extracted using a Qiagen plasmid Maxikit (Qiagen, Valencia, CA), followed by electroporation into *Escherichia coli* DH10B (Invitrogen) using a Gene Pulser II instrument (Bio-Rad Laboratories). *E. coli* DH10B transformants were selected on Luria-Bertani (LB) agar plates containing 100 $\mu\text{g/ml}$ ampicillin or 1 $\mu\text{g/ml}$ imipenem and then screened by multiplex real-time PCR for the presence of *bla*_{KPC} genes (23). Plasmid size was estimated by S1 nuclease digestion of plasmid DNA, followed by pulsed-field gel electrophoresis (PFGE) using a Bio-Rad CHEF-DR III variable-angle system (26). Transformants with a single plasmid were then selected and subjected to susceptibility testing as described above. Plasmids isolated from *E. coli* DH10B transformants were digested with restriction endonuclease EcoRV (New England BioLabs, Boston, MA), and their restriction patterns were compared. Transferability of *bla*_{KPC-4}⁻ and *bla*_{KPC-5}⁻-bearing plasmids was examined by conjugation experiments using three clinical isolates (BK31551, BK31572, and BK31567) as donors and *E. coli* J53Az^r as the recipient as described previously (27). *E. coli* J53 transconjugants with KPC-encoding plasmids were selected on LB plates containing 50 $\mu\text{g/ml}$ sodium azide and 100 $\mu\text{g/ml}$ ampicillin. The presence of the *bla*_{KPC-4} or *bla*_{KPC-5} gene in *E. coli* J53 transconjugants was confirmed by the aforementioned multiplex real-time PCR (23).

Plasmid incompatibility groups were determined using the multiplex PCR method described by Carattoli et al. (28). β -Lactamase genes, including *bla*_{CTX-M}, *bla*_{SHV}, *bla*_{TEM}, *bla*_{GES}, *bla*_{NDM}, *bla*_{VIM}, *bla*_{IMP}, *bla*_{OXA-48}, *bla*_{ACT-1}, *bla*_{ACC}, *bla*_{BIL-1}, *bla*_{CMY}, *bla*_{DHA}, *bla*_{FOX}, *bla*_{LAT}, *bla*_{MIR-1}, and *bla*_{MOX}, were investigated by PCR using methods described elsewhere (29, 30). Multilocus sequence typing (MLST) of the parental strains (31) and plasmid MLST for IncN group plasmids (32) were performed using previously described methods. OmpK35 and OmpK36 porins were analyzed by SDS-PAGE, and their genes were amplified by PCR followed by DNA sequencing (33).

Plasmid sequencing and bioinformatics. Plasmid DNA from *E. coli* DH10B transformants of BK31551 (KPC-4) and BK31567 (KPC-5) were extracted as described above using a Qiagen plasmid Maxikit (Qiagen, Valencia, CA). The plasmid DNA was fragmented, and genomic libraries

were prepared and sequenced using a Roche 454 GS-FLX system. Sequencing reads were assembled into consensus *de novo* assembly contigs using the Roche genome sequencer FLX software GSA assembler, version 2.5.3. Gaps between contigs were closed by PCR with standard Sanger sequencing.

Open reading frames (ORFs) were predicted and annotated using the RAST (rast.nmpdr.org) server (34), followed by manual comparative curation and sequence similarity searches directed against the NCBI (www.ncbi.nlm.nih.gov/BLAST) and IS Finder (www-is.biotoul.fr) databases. MEGA 5.01 was used for sequences comparison and alignment (35). Mauve 2.3.1 was used to perform comparative genome alignment for different plasmids (36).

Nucleotide sequence accession numbers. The complete nucleotide sequences of pBK31551 and pBK31567 have been deposited in GenBank under accession numbers JX193301 and JX193302, respectively.

RESULTS

Characteristics of clinical isolates. Genotyping of the 27 carbapenem-resistant isolates indicated that they all possessed the *bla*_{KPC} genes, including *bla*_{KPC-3} ($n = 22$; 81.5%) and *bla*_{KPC-2} ($n = 2$; 7.4%), while three strains were unexpectedly identified with *bla*_{KPC-4} ($n = 2$) and *bla*_{KPC-5} ($n = 1$). With the exception of one isolate, all *bla*_{KPC-2}⁻ and *bla*_{KPC-3}⁻-harboring strains belonged to the epidemic *K. pneumoniae* ST258 clone (22); however, neither the *bla*_{KPC-4}⁻ nor the *bla*_{KPC-5}⁻-carrying strains were ST258. Multilocus sequence typing (31) indicated that the three non-ST258 isolates belonged to uncommon sequence types (STs): ST834 (2-1-2-1-7-1-25), strain BK31551; ST964 (41-1-1-1-7-4-87), strain BK31572; and ST429 (2-1-2-1-9-1-116), strain BK31567. The differing PFGE profiles of these three strains also indicated they were not genetically related (data not shown). S1-PFGE on different *E. coli* DH10B transformants revealed that each strain carried a single plasmid ranging in size from 49 to 84 kb (49 kb for pBK31567, 75 kb for pBK31572, and 84 kb for pBK31551). Conjugation experiments showed that three *bla*_{KPC-4}⁻ and *bla*_{KPC-5}⁻-harboring plasmids could be successfully transferred to *E. coli* J53 recipients. In addition, SDS-PAGE and DNA sequence analysis showed no evidence of porin loss of OmpK35 and OmpK36 in three parental strains (data not shown).

A list of antimicrobial agents and their MICs against KPC-4- or -5-producing clinical isolates (and their transformants) is shown in Table 1. The parental strains were resistant to aztreonam, ceftaxime, ceftazidime, ticarcillin/clavulanate, and trimethoprim-sulfamethoxazole, to imipenem (BK31572), and to ertapenem (BK31572 and BK31567) and exhibited reduced susceptibility to piperacillin-tazobactam. In addition, BK31551 and BK31567 displayed intermediate resistance to imipenem (MIC 2 $\mu\text{g/ml}$), while BK31572 displayed intermediate resistance to doripenem (MIC 2 $\mu\text{g/ml}$) (25). The *E. coli* DH10B transformants displayed antimicrobial susceptibility profiles similar to those of their parental strains but were not as resistant to imipenem, ertapenem, and doripenem (Table 1). Notably, although some of the MIC values in Table 1 fall within the susceptibility range for carbapenems (≤ 1 $\mu\text{g/ml}$ for imipenem, meropenem, and doripenem and ≤ 0.5 $\mu\text{g/ml}$ for ertapenem), they are nevertheless higher than those reported previously for wild-type *K. pneumoniae* strains (without carbapenemase or porin loss) (37).

Structure of *bla*_{KPC-4}-harboring plasmid pBK31551. Plasmid pBK31551 is a circular molecule of 83,712 bp belonging to incompatibility group N, with an average GC content of 53.4%, and harboring 80 predicted ORFs (Fig. 1). The plasmid com-

TABLE 1 Characteristics of KPC-4- and KPC-5-producing *K. pneumoniae* strains and their *E. coli* DH10B transformants

Isolate ^a	β-Lactamase(s)	MIC (μg/ml) ^b																		
		IMP	MER	ERT	DOR	CAZ	CTX	CEF	ATM	TIC-CLAV	PIP-TAZ	AMI	TOB	DOX	CIP	LEV	SXT	TGC	COL	PLB
BK31551	TEM-1, SHV-11, KPC-4	2	0.5	1	1	>16	>32	4	>16	128/2	64/4	≤4	≤1	>16	1	2	>4/76	1	0.5	1
T-BK31551	TEM-1, KPC-4	1	0.5	0.5	0.5	>16	16	8	>16	>128/2	>64/4	≤4	4	≤2	≤0.25	≤1	>4/76	≤0.25	≤0.25	0.5
BK31572	TEM-1, SHV-11, KPC-4	4	1	4	2	>16	>32	4	>16	>128/2	>64/4	≤4	≤1	≤2	≤0.25	≤1	>4/76	≤0.25	0.5	1
T-BK31572	TEM-1, KPC-4	2	1	1	0.5	>16	>32	8	>16	>128/2	64/4	≤4	2	2	≤0.25	≤1	>4/76	≤0.25	≤0.25	0.5
BK31567	SHV-1, KPC-5	2	1	4	0.5	>16	32	≤2	>16	>128/2	>64/4	≤4	≤1	4	>2	≤1	>4/76	1	0.5	1
T-BK31567	KPC-5	1	0.5	0.5	0.5	>16	4	≤2	>16	>128/2	16/4	≤4	≤1	≤2	≤0.25	≤1	>4/76	≤0.25	≤0.25	0.5

^a T-, *E. coli* DH10B transformant.

^b MICs were determined using broth microdilution; resistance is indicated in boldface. IMP, imipenem; MER, meropenem; ERT, ertapenem; DOR, doripenem; CAZ, ceftazidime; CTX, cefotaxime; CEF, cefepime; ATM, aztreonam; TIC-CLAV, ticarcillin-clavulanate; PIP-TAZ, piperacillin-tazobactam; AMI, amikacin; TOB, tobramycin; DOX, doxycycline; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; COL, colistin; PLB, polymyxin B. The 2012 CLSI breakpoints were used to interpret the MIC results for carbapenem-susceptible (S), -intermediate (I), and -resistant (R) isolates, as follows (S/I/R): imipenem, ≤1/2/≥4 μg/ml; meropenem, ≤1/2/≥4 μg/ml; ertapenem, ≤0.5/1/≥2 μg/ml; and doripenem ≤1/2/≥4 μg/ml (25).

prises a 37,343-bp core region and two discontinuous acquired regions (42,924 and 3,445 bp). The core region defines plasmid “housekeeping genes,” including a replication module, two transfer (*tra*) systems, a stability operon, and an antirestriction system (Fig. 1). The two discontinuous acquired regions are composed of numerous resistance genes, insertion sequences, and transposons (Fig. 1).

The core genes in pBK31551 and other IncN plasmids are clustered into different functional modules (Fig. 1). The replication region includes a 720-bp replication initiation protein gene (*repA*), flanked by direct repeat sequences and adjacent to a resolvase gene (*uvp1* or *resP*) required for resolving cointegrates at the end of replication (38). pBK31551 also possesses two modules

that are predicted to be involved in the conjugative transfer of plasmid DNA. The first module consists of 11 genes (*traL*, *traM*, *traA*, *traB*, *traC*, *traD*, *traN*, *traE*, *traO*, *traF*, and *traG*) flanked by a group of plasmid core genes involved in regulating transfer and replication (*korA* and *korB*) (39), excluding DNA entry (*eex*) (40), DNA degradation (*nuc*) (41), and killing of *Klebsiella* (*kikA*) (42, 43) (Fig. 1). The second module includes three genes (*traI*, *traJ*, and *traK*) that also function in replication and DNA transfer, while the *fipA* gene, located upstream of *traI*, functions in fertility inhibition of IncP plasmids (44).

Additional core genes common to IncN plasmids and found on pBK31551 contribute to plasmid stability. The restriction/antirestriction system encoded by the *EcoRII* and *EcoRII met* genes prob-




FIG 1 Comparative analysis of IncN plasmids pBK31551 (JX193301), pK96 (EU195449), p9 (FJ223607), pR46 (AY046276), pKOX105 (HM126012), and p12 (FJ223605). Light blue shading denotes shared regions of homology. It is noted that the region between *kikA* and *nuc* is inverted in pKOX105 relative to the other plasmids and is split into two regions in p12 due to the insertion of the *ars* operon. Open reading frames (ORFs) are portrayed by arrows and colored based on predicted gene function. Resistance genes are indicated in red arrows and include aminoglycoside resistance genes [*aph* (3′)-I, *aac*(3)-Ib, *aac*(6′)-Ib-cr, *aph*, *aadA1*, and *aacA4*], β-lactamase genes (*bla*_{KPC-2}, *bla*_{KPC-3}, *bla*_{KPC-4}, *bla*_{KPC-5}, *bla*_{VIM-1}, *bla*_{CTX-M-24}, *bla*_{OXA-2}, *bla*_{OXA-9}, *bla*_{TEM-1}, *bla*_{SHV-12}, and *ampR*), quinolone resistance genes (*qnrA1*, *qnrB2*, and *qnrS1*), arsenic resistance genes (*arsA*, *arsB*, *arsC*, *arsD*, and *arsR*), tetracycline resistance genes (*tetA* and *tetR*), and quaternary compound, trimethoprim, and sulfonamide resistance genes (*sulI*, *qacF*, *qacEΔ1*, and *dfrA14*), as well as glyoxalase/bleomycin resistance gene *glo*, alcohol dehydrogenase gene *adh*, and S-formylglutathione hydrolase gene *fgh*.

ably functions as a toxin/antitoxin system to lyse cells which have lost the plasmid (45). Genes located downstream of the *traIJK* modules for conjugative transfer were also predicted to play a role in plasmid stability. Specifically, the proteins encoded by the *stbABC* operon are believed to stabilize single-stranded DNA during conjugation (46), while *ardAB* and *ardR* encode proteins involved in regulating antirestriction functions (47, 48). pBK31551 also possesses *ccg* genes (cup-controlled genes), which encode products involved in the protection of plasmid DNA from type I restriction enzymes (48).

The pBK31551 plasmid also has two distinct regions harboring antibiotic resistance genes. A 3,445-bp region downstream of the *uvp1* gene includes a class I integron with a 3' conserved sequence (3' CS) truncated by insertion of an IS6100 element. This integron contains the *dfrA14* gene cassette, which confers trimethoprim resistance.

The primary cluster of resistance genes in pBK31551 is located in a 42,924-bp region between genes *fipA* and *nuc* and includes β -lactamase genes *bla*_{KPC-4} and *bla*_{TEM-1}, aminoglycoside resistance genes *aph(3')-I* and *aac(3)-Ib*, quinolone resistance gene *qnrB2*, quaternary compound resistance genes *qacF* and *qacE Δ 1*, sulfonamide resistance gene *sul1*, glyoxalase/bleomycin resistance gene *glo*, alcohol dehydrogenase gene *adh*, and S-formylglutathione hydrolase gene *fgh*.

Within this 42,924-bp region, an 18,282-bp fragment contains the Tn4401 element harboring the *bla*_{KPC-4} gene, which encodes the carbapenemase. The insertion of the element, which disrupted the Tn3 transposase gene, generated a 5-bp (AAAGC) target sequence duplication (TSD) at each end of Tn4401 (Fig. 1). Surprisingly, sequencing of the Tn4401 element identified a unique 8,271-bp insertion which disrupted the *istA* gene and generated a 5-bp TSD (ACCGG). This insertion contains two discrete elements: a 1,395-bp insertion sequence that belongs to the IS110 family and is 91% similar to an insertion sequence in *Yersinia pestis* plasmid pMT (www.ncbi.nlm.nih.gov/GenBank) and a 6,876-bp region that is 99.7% similar to the Tn3 family transposon Tn6901 (49). Tn6901 carries 6 genes, including a transposase gene, a resolvase gene, an alcohol dehydrogenase gene (*adh*), a glyoxalase/bleomycin resistance gene (*glo*), an S-formylglutathione hydrolase gene (*fgh*), and a regulator protein gene (*frmR*). The *bla*_{KPC-4} gene is located downstream of Tn6901 and displays 100% identity to previously reported *bla*_{KPC-4} sequences from *Enterobacter cancerogenus* strain E624 (FJ473382) and *K. pneumoniae* strain KpAM1 (EU447304).

There are two additional genetic elements located upstream of Tn4401 (Fig. 1). Transposon Tn1721 is flanked by a class I integron, consisting of *aac(3)-Ib*, *qacF*, *qacE Δ 1*, and *sul1*. The next element consists of a truncated class I integron containing *sapA*, *qnrB2*, Δ *qacE Δ 1*, *sul1*, and two unknown ORFs, as well as an ISCR1 element inserted within the 5' conserved sequence (5' CS). Acquired genes located downstream of Tn4401 include IS1294, *aph(3')-I*, *bla*_{TEM-1}, and the transposase (*tnpA*) and resolvase (*tnp*) genes of Tn3.

Comparison of pBK31551 with IncN plasmids. pBK31551 was compared to IncN prototype plasmid pR46 (AY046276) as well as several other *bla* gene-carrying IncN plasmids, including pKP96 (EU195449), p9 (FJ223607), pKOX105 (HM126012), and p12 (FJ223605) (Fig. 1). All plasmids shared similarities in core genes responsible for plasmid maintenance, including replication, transfer, and stability systems (Fig. 1). Plasmids p12 and

pKOX105 lack the antirestriction genes *ccgC*, *ccgD*, and *ardA*, while p12 has a nonfunctional transfer region due to insertion of an arsenic resistance operon (*ars*) between *traB* and *traA*. In pKOX105, moreover, the region containing the *traAB* operon (from *nuc* to *kikA*) is inverted relative to that in other IncN plasmids.

The major differences among these plasmids are related to the number of acquired genes (Fig. 1). Interestingly, these plasmids possess similar integration sites. For example, with the exception of plasmid p9, the IncN plasmids all share integration of a class I integron downstream of the *uvp1* gene (Fig. 1). Similarly, the 42-kb antibiotic resistance region inserted between the *fipA* and *nuc* genes in pBK31551 closely resembles the acquired resistance genes in p12 (also located between *fipA* and *nuc*), pKOX105 (between EcoRII and *fipA*), and pKP96 (between *nuc* and *traI*). Thus, although pBK31551 and other IncN plasmids carry different antibiotic resistance genes, they share similar integration sites for the acquisition of variable resistance determinants, which may represent entry sites or "hot spots" for integration of transposable elements within the IncN plasmid scaffold (17).

Characterization of pBK31572. Given the unusual Tn6901 and IS110 insertions within Tn4401 in pBK31551, we investigated additional insertions within other KPC-harboring isolates, including another KPC-4-producing strain (BK31572) isolated in 2006. PCR assays targeting both insertion junctions as well as *istA* showed negative results for all *bla*_{KPC-2}- or *bla*_{KPC-3}-harboring strains (data not shown). Interestingly, pBK31572 possesses the same Tn6901 and IS110 insertions as pBK31551, as demonstrated by PCR (data not shown). Comparative restriction enzyme digests of pBK31551 and pBK31572 using EcoRV displayed similar profiles, suggesting genetic relatedness (data not shown). Plasmid MLST (32) results also showed that both pBK31551 and pBK31572 belong to IncN ST6 (2-4-2), the same genotype described previously for KPC-3-producing strain p12, isolated in 2005 (10). Additional PCR assays used to detect *bla*_{TEM-1} (29), *aac(3)-Ib* (50), *qnrB2* (51), and *aph(3')-I* (52) in pBK31551 showed that pBK31572 was negative for *qnrB2* but positive for other three targets. Nevertheless, in addition to Tn4401, pBK31572 and pBK31551 appear to share similar backbone genes, with the observed size differences likely due to variable content within acquired genetic elements.

Structure of *bla*_{KPC-5}-harboring plasmid pBK31567. Plasmid pBK31567 is a circular molecule of 47,387 bp, with an average GC content of 49.0%, and harboring 54 predicted ORFs (Fig. 2A). Sequence analysis of pBK31567 classified it within plasmid incompatibility group X, and we have further typed it as a novel IncX subgroup (IncX5) (described below). The IncX group of plasmids are narrow-host-range plasmids common in *Enterobacteriaceae*, and they exist even in isolates from the preantibiotic era (53). They are known to encode type IV fimbriae enabling their own conjugative transfer, and they provide accessory functions to their host bacteria such as biofilm formation and resistance to antimicrobial agents (54). IncX plasmids possess highly syntenic plasmid backbones but are quite divergent with respect to nucleotide and amino acid similarity (54). Based on phylogenetic comparisons of sequenced IncX plasmids, the IncX plasmid group has been divided into at least four subgroups, IncX1 to IncX4 (54).

Previous studies indicated that the characteristic structure of the IncX plasmid group includes a set of core genes positioned in the following order: *pir-bis-par-hns-topB-pilX-actX-taxCA* (54,




FIG 2 (A) Structure of plasmid pBK31567. Open reading frames (ORFs) are portrayed by arrows, with backbone region ORFs in dark gray and acquired region ORFs in white. Core backbone genes in pBK31567 are shown in boldface. Resistance genes are depicted by black arrows, including β -lactamase genes (*bla*_{KPC-5}) and quaternary compound, trimethoprim, and sulfonamide resistance genes (*qacF*, *qacE Δ 1*, *dfrA5*, and *sulI*). (B) Phylogenetic maximum-likelihood tree of single nucleotide polymorphisms (SNPs) from backbone sequences of 19 IncX plasmids, including (GenBank accession numbers are shown in parentheses) pBK31567 (JX193302), p2ESCUM (CU928149), pBS512_33 (CP001059), pCROD2 (FN543504), pDKX1-TEM-52 (JQ269336), pE001 (JF776874), pEC14_35 (JN935899), plncX-SHV (JN247852), pJIE143 (JN194214), pLN126_33 (HE578058), pMAS2027 (FJ666132), pNGX2-QnrS1 (JQ269335), pNMEC31_31 (JN935897), pOLA52 (EU370913), pOU1114 (DQ115387), pRPEC180_47 (JN935898), pSE34 (EU219533), pUMNF18_32 (AGTD1000006), and pX1.0 (HM114226). All plasmids from a previous study (54), as well as pBK31567, have been included for phylogenetic analysis.

55). These same core genes are found in the backbone region of pBK3156

in pBK31567. The Tn4401 region of pBK31567 displayed 99.9% similarity with the sequences of previously described Tn4401 elements from p9 and p12 (10), with the only observed sequence variation associated with their respective *bla*_{KPC} variants (*bla*_{KPC-5} versus *bla*_{KPC-2/-3}). An intact class I integron, located downstream of the Tn4401 and IS6100 elements, harbors the trimethoprim resistance gene *dfpA5*, the quaternary compound resistance gene *qacEΔ1*, and the sulfonamide resistance gene *sul1*. To the best of our knowledge, this is the first description of a carbapenemase gene (*bla*_{KPC}) and a class I integron carried on the same IncX plasmid.

DISCUSSION

Currently, KPC-2 and KPC-3 carbapenemases have been described in multiple Gram-negative species, including various *Enterobacteriaceae*, and several *bla*_{KPC-2}- and *bla*_{KPC-3}-harboring plasmids have been fully sequenced (2, 4, 6, 10, 16). In contrast, strains harboring *bla*_{KPC-4}- and *bla*_{KPC-5}-carrying plasmids are rarely reported, and these plasmids have not been completely analyzed. As of this writing, *bla*_{KPC-4} has been reported in three isolates: *E. cancerogenus* strain E624 from Scotland, isolated in 2003 (56), and *K. pneumoniae* strain KpAM1 (57) and *Acinetobacter* sp. strain M2AC9-31 (58), isolated in Puerto Rico in 2006 and 2009, respectively. Similarly, *bla*_{KPC-5} has been found only in *Pseudomonas aeruginosa* strain PS28 (PR280) and in isolates in Puerto Rico between October 2006 and March 2007 (14, 59).

In this study, we characterized complete sequences of *bla*_{KPC-4}- and *bla*_{KPC-5}-harboring plasmids pBK31551 and pBK31567, isolated from a single hospital in New Jersey, revealing a number of unusual findings. First, a large element carrying both IS110 and Tn6901 (8.3 kb) was found inserted within Tn4401 in pBK31551 (Fig. 1), and the same element was also identified in plasmid pBK31572. Both plasmids were also shown to have the same plasmid MLST profile, supporting their genetic relatedness, although pBK31572 is smaller and lacks certain antibiotic resistance genes present in pBK31551. Insertions and genetic alterations have been previously described in Tn4401 adjacent to the *bla*_{KPC} genes (9, 13, 14), including a previous study in which we described a 5.3-kb deletion within Tn4401 encompassing all of IS*Kpn7* (*istA* and *istB*), 80% of *tnpA*, and 60% of *bla*_{KPC} (33). The genetic diversity associated with Tn4401 underlines the notion that the region surrounding *bla*_{KPC} undergoes significant recombination.

The insertion of Tn6901 and IS110 upstream of *bla*_{KPC} raises the possibility that they may alter gene expression and the level of carbapenem resistance. In fact, both KPC-4-producing *K. pneumoniae* strains displayed low-level resistance to carbapenems, with MIC values of 1 to 4 μg/ml, 2 to 4 μg/ml, and 1 to 2 μg/ml for ertapenem, imipenem, and doripenem, respectively, and total susceptibility to meropenem (Table 1). In addition, the *E. coli* DH10B *bla*_{KPC-4} transformants were even more susceptible than the parental strains, providing further evidence that the host influences plasmid gene expression levels. In contrast, the KPC-4 resistance reported in *E. cancerogenus* strain E624 exhibited higher MIC levels against imipenem (>32 μg/ml), meropenem (>32 μg/ml), and ertapenem (>16 μg/ml) (14). Significantly, sequence analysis of the 363-bp region upstream of *bla*_{KPC-4} in pBK31551, including the putative promoter region (60), showed that these upstream sequences are identical to that found in the *E. cancerogenus* strain E624 plasmid, raising speculation that the difference in MICs could be related to the IS110 and Tn6901 insertions in

Tn4401 or else to other factors such as a combination of porin loss/alteration and β-lactamases (extended-spectrum β-lactamases or AmpC enzymes) in *E. cancerogenus* strain E624.

The second unusual finding was the identification of a KPC-5-producing *K. pneumoniae* strain in which the *bla*_{KPC-5}-harboring Tn4401 element was located on a plasmid belonging to a novel IncX subgroup (IncX5). IncX plasmids have been implicated in the acquisition and dissemination of transferrable drug resistance in different *Enterobacteriaceae* spp. (54) and have been shown to be transferrable from *E. coli* to *P. aeruginosa* (61). Although various resistance determinants have been described in IncX plasmids, carbapenemases have not been identified previously. It is therefore likely that pBK31567 originated from an IncX5 plasmid which acquired Tn4401 and the class I integron by horizontal transfer. Interestingly, the *bla*_{KPC-5} gene was initially described in *P. aeruginosa* strain PS28 and notably was not located on Tn4401 (14). Instead, the carbapenemase gene was located within a novel genetic environment, with Tn5563- and IS6100-related elements inserted upstream of *bla*_{KPC-5}. The differences in the flanking regions of *bla*_{KPC-5} observed between PS28 and BK31567 indicate that *bla*_{KPC-5} is not associated with the unique genetic environment described in strain *P. aeruginosa* strain PS28. It is interesting that strain BK31567 was isolated in the same year (2006) as strain PS28 (14, 59); however, data on patient demographics are unknown for this isolate (PS28). Likewise, neither the complete plasmid sequence nor the Inc group of the PS28 plasmid is available, precluding direct sequence comparisons between these two plasmids. Consequently, the relationship between these two *bla*_{KPC-5}-harboring plasmids remains unclear.

Previous sequence comparison between different *bla*_{KPC} variants showed that *bla*_{KPC-3}, *bla*_{KPC-5}, and *bla*_{KPC-6} each differ from *bla*_{KPC-2} by a single nucleotide change, while *bla*_{KPC-5} and *bla*_{KPC-6} also differ from *bla*_{KPC-4} by a single nucleotide (14, 23). Accordingly, it was hypothesized that *bla*_{KPC-4} may have emerged through a sequential process, wherein *bla*_{KPC-5} and/or *bla*_{KPC-6} represents an intermediate step (14, 23). Interestingly, KPC-4 and -5 were both identified in the same hospital; nevertheless, evidence that the *bla*_{KPC-4} gene in pBK31551 or pBK31572 evolved directly from *bla*_{KPC-5} in pBK31567 is lacking, as these genes were found in distinct plasmids from diverse genetic backgrounds and different time periods.

In this study, we have described in detail the complete sequences of IncN and IncX plasmids harboring *bla*_{KPC-4} and *bla*_{KPC-5} carbapenemase genes. Comparative genomic analyses provide new insights into the evolution and dissemination of KPC-producing carbapenem resistance plasmids belonging to different incompatibility groups. Our studies and previous investigations highlight the essential roles of Tn4401 in KPC dissemination and evolution, including large-scale deletions, insertions, and replacements, as well as carriage of different *bla*_{KPC} variants and horizontal transfer between different plasmids and host strains.

ACKNOWLEDGMENTS

This study was supported by a grant (to B.N.K.) from the National Institutes of Health (1R01AI090155). This work was supported in part by the Veterans Affairs Merit Review Program (R.A.B.), the National Institutes of Health (grants AI072219-05 and AI063517-07 to R.A.B.), and the Geriatric Research Education and Clinical Center VISN 10 (R.A.B.).

We thank the team from Genotyping of Pathogens and Public Health (Institut Pasteur, Paris, France) for curating the MLST profiles and isolates databases at www.pasteur.fr/mlst.

REFERENCES

- Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant *Enterobacteriaceae*: epidemiology and prevention. *Clin. Infect. Dis.* 53:60–67.
- Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing *Enterobacteriaceae*. *Emerg. Infect. Dis.* 17:1791–1798.
- Nordmann P, Cuzon G, Naas T. 2009. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect. Dis.* 9:228–236.
- Andrade LN, Curiao T, Ferreira JC, Longo JM, Climaco EC, Martinez R, Bellissimo-Rodrigues F, Basile-Filho A, Evaristo MA, Del Peloso PF, Ribeiro VB, Barth AL, Paula MC, Baquero F, Canton R, Darini AL, Coque TM. 2011. Dissemination of *bla*_{KPC-2} by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncL/M) among *Enterobacteriaceae* species in Brazil. *Antimicrob. Agents Chemother.* 55:3579–3583.
- Baraniak A, Grabowska A, Izdebski R, Fiett J, Herda M, Bojarska K, Zabicka D, Kania-Pudlo M, Mlynarczyk G, Zak-Pulawska Z, Hryniewicz W, Gniadkowski M. 2011. Molecular characteristics of KPC-producing *Enterobacteriaceae* at the early stage of their dissemination in Poland, 2008–2009. *Antimicrob. Agents Chemother.* 55:5493–5499.
- Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P. 2010. Worldwide diversity of *Klebsiella pneumoniae* that produce β -lactamase *bla*_{KPC-2} gene. *Emerg. Infect. Dis.* 16:1349–1356.
- Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob. Agents Chemother.* 53:3365–3370.
- Cuzon G, Naas T, Villegas MV, Correa A, Quinn JP, Nordmann P. 2011. Wide dissemination of *Pseudomonas aeruginosa* producing β -lactamase *bla*_{KPC-2} gene in Colombia. *Antimicrob. Agents Chemother.* 55:5350–5353.
- Gomez SA, Pasteran FG, Faccone D, Tijet N, Rapoport M, Lucero C, Lastovetska O, Albornoz E, Galas M, Melano RG, Corso A, Petroni A. 2011. Clonal dissemination of *Klebsiella pneumoniae* ST258 harbouring KPC-2 in Argentina. *Clin. Microbiol. Infect.* 17:1520–1524.
- Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC. 2009. Genetic organization of transposase regions surrounding *bla*_{KPC} carbapenemase genes on plasmids from *Klebsiella* strains isolated in a New York City hospital. *Antimicrob. Agents Chemother.* 53:1998–2004.
- Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, Patel JB. 2010. Genetic factors associated with elevated carbapenem resistance in KPC-producing *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 54:4201–4207.
- Naas T, Cuzon G, Villegas M-V, Lartigue M-F, Quinn JP, Nordmann P. 2008. Genetic structures at the origin of acquisition of the β -lactamase *bla*_{KPC} gene. *Antimicrob. Agents Chemother.* 52:1257–1263.
- Shen P, Wei Z, Jiang Y, Du X, Ji S, Yu Y, Li L. 2009. Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among *Enterobacteriaceae* in China. *Antimicrob. Agents Chemother.* 53:4333–4338.
- Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. 2009. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. *Antimicrob. Agents Chemother.* 53:557–562.
- Cuzon G, Naas T, Nordmann P. 2011. Functional characterization of Tn4401, a Tn3-based transposon involved in *bla*_{KPC} gene mobilization. *Antimicrob. Agents Chemother.* 55:5370–5373.
- Mataseje LF, Boyd DA, Willey BM, Prayitno N, Kreiswirth N, Gelosia A, Poutanen SM, Low DE, Jenkins SG, Katz K, Mulvey MR. 2011. Plasmid comparison and molecular analysis of *Klebsiella pneumoniae* harbouring *bla*_{KPC} from New York City and Toronto. *J. Antimicrob. Chemother.* 66:1273–1277.
- Carattoli A, Aschbacher R, March A, Larcher C, Livermore DM, Woodford N. 2010. Complete nucleotide sequence of the IncN plasmid pKOX105 encoding VIM-1, QnrS1 and SHV-12 proteins in *Enterobacteriaceae* from Bolzano, Italy compared with IncN plasmids encoding KPC enzymes in the USA. *J. Antimicrob. Chemother.* 65:2070–2075.
- Garcia-Fernandez A, Villa L, Carta C, Venditti C, Giordano A, Venditti M, Mancini C, Carattoli A. 2012. *Klebsiella pneumoniae* ST258 producing KPC-3 identified in Italy carries novel plasmids and OmpK36/OmpK35 porin variants. *Antimicrob. Agents Chemother.* 56:2143–2145.
- Jiang Y, Yu D, Wei Z, Shen P, Zhou Z, Yu Y. 2010. Complete nucleotide sequence of *Klebsiella pneumoniae* multidrug resistance plasmid pKP048, carrying *bla*_{KPC-2}, *bla*_{DHA-1}, *qnrB4*, and *armA*. *Antimicrob. Agents Chemother.* 54:3967–3969.
- Leavitt A, Chmelnitsky I, Carmeli Y, Navon-Venezia S. 2010. Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic *Klebsiella pneumoniae* sequence type 258. *Antimicrob. Agents Chemother.* 54:4493–4496.
- Liu P, Li P, Jiang X, Bi D, Xie Y, Tai C, Deng Z, Rajakumar K, Ou HY. 2012. Complete genome sequence of *Klebsiella pneumoniae subsp. pneumoniae* HS11286, a multidrug-resistant strain isolated from human sputum. *J. Bacteriol.* 194:1841–1842.
- Chen L, Chavda KD, Mediavilla JR, Zhao Y, Framow HS, Jenkins SG, Levi MH, Hong T, Rojtmán AD, Ginocchio CC, Bonomo RA, Kreiswirth BN. 2012. Multiplex real-time PCR for detection of an epidemic KPC-producing *Klebsiella pneumoniae* ST258 clone. *Antimicrob. Agents Chemother.* 56:3444–3447.
- Chen L, Mediavilla JR, Endimiani A, Rosenthal ME, Zhao Y, Bonomo RA, Kreiswirth BN. 2011. Multiplex real-time PCR assay for detection and classification of *Klebsiella pneumoniae* carbapenemase gene (*bla*_{KPC}) variants. *J. Clin. Microbiol.* 49:579–585.
- Schechner V, Straus-Robinson K, Schwart D, Pfeffer I, Tarabeia J, Moskovich R, Chmelnitsky I, Schwaber MJ, Carmeli Y, Navon-Venezia S. 2009. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the *Enterobacteriaceae* family. *J. Clin. Microbiol.* 47:3261–3265.
- CLSI. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement, M100-S22. CLSI, Wayne, PA.
- Barton BM, Harding GP, Zuccarelli AJ. 1995. A general method for detecting and sizing large plasmids. *Anal. Biochem.* 226:235–240.
- Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. 2003. Plasmid-mediated quinolone resistance in clinical isolates of *Escherichia coli* from Shanghai, China. *Antimicrob. Agents Chemother.* 47:2242–2248.
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J. Microbiol. Methods* 63:219–228.
- Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in *Enterobacteriaceae*. *J. Antimicrob. Chemother.* 65:490–495.
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn. Microbiol. Infect. Dis.* 70:119–123.
- Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J. Clin. Microbiol.* 43:4178–4182.
- Garcia-Fernandez A, Villa L, Moodley A, Hasman H, Miriagou V, Guardabassi L, Carattoli A. 2011. Multilocus sequence typing of IncN plasmids. *J. Antimicrob. Chemother.* 66:1987–1991.
- Chen L, Chavda KD, Mediavilla JR, Jacobs MR, Levi MH, Bonomo RA, Kreiswirth BN. 2012. Partial excision of *bla*_{KPC} from Tn4401 in carbapenem-resistant *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 56:1635–1638.
- Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formisano K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. doi: 10.1186/1471-2164-9-75.
- Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* 28:2731–2739.

36. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. *PLoS One* 5:e111147. doi:10.1371/journal.pone.0011147.
37. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, Hujer AM, Bethel CR, Bonomo RA, Jacobs MR. 2010. Evaluation of updated interpretative criteria for categorizing *Klebsiella pneumoniae* with reduced carbapenem susceptibility. *J. Clin. Microbiol.* 48:4417–4425.
38. Papp PP, Iyer VN. 1995. Determination of the binding sites of RepA, a replication initiator protein of the basic replicon of the IncN group plasmid pCU1. *J. Mol. Biol.* 246:595–608.
39. More MI, Pohlman RF, Winans SC. 1996. Genes encoding the pKM101 conjugal mating pore are negatively regulated by the plasmid-encoded KorA and KorB proteins. *J. Bacteriol.* 178:4392–4399.
40. Pohlman RF, Genetti HD, Winans SC. 1994. Entry exclusion of the IncN plasmid pKM101 is mediated by a single hydrophilic protein containing a lipid attachment motif. *Plasmid* 31:158–165.
41. Pohlman RF, Liu F, Wang L, More MI, Winans SC. 1993. Genetic and biochemical analysis of an endonuclease encoded by the IncN plasmid pKM101. *Nucleic Acids Res.* 21:4867–4872.
42. Hengen PN, Denicourt D, Iyer VN. 1992. Isolation and characterization of *kikA*, a region on IncN group plasmids that determines killing of *Klebsiella oxytoca*. *J. Bacteriol.* 174:3070–3077.
43. Rodriguez M, Holcik M, Iyer VN. 1995. Lethality and survival of *Klebsiella oxytoca* evoked by conjugative IncN group plasmids. *J. Bacteriol.* 177:6352–6361.
44. Santini JM, Stanisich VA. 1998. Both the *ftpA* gene of pKM101 and the *pifC* gene of F inhibit conjugal transfer of RP1 by an effect on *traG*. *J. Bacteriol.* 180:4093–4101.
45. Kulakauskas S, Lubys A, Ehrlich SD. 1995. DNA restriction-modification systems mediate plasmid maintenance. *J. Bacteriol.* 177:3451–3454.
46. Paterson ES, More MI, Pillay G, Cellini C, Woodgate R, Walker GC, Iyer VN, Winans SC. 1999. Genetic analysis of the mobilization and leading regions of the IncN plasmids pKM101 and pCU1. *J. Bacteriol.* 181:2572–2583.
47. Belogurov AA, Delver EP, Rodzevich OV. 1993. Plasmid pKM101 encodes two nonhomologous antirestriction proteins (ArdA and ArdB) whose expression is controlled by homologous regulatory sequences. *J. Bacteriol.* 175:4843–4850.
48. Delver EP, Belogurov AA. 1997. Organization of the leading region of IncN plasmid pKM101 (R46): a regulation controlled by CUP sequence elements. *J. Mol. Biol.* 271:13–30.
49. Murata T, Ohnishi M, Ara T, Kaneko J, Han CG, Li YF, Takashima K, Nojima H, Nakayama K, Kaji A, Kamio Y, Miki T, Mori H, Ohtsubo E, Terawaki Y, Hayashi T. 2002. Complete nucleotide sequence of plasmid Rts1: implications for evolution of large plasmid genomes. *J. Bacteriol.* 184:3194–3202.
50. Schwocho LR, Schaffner CP, Miller GH, Hare RS, Shaw KJ. 1995. Cloning and characterization of a 3-N-aminoglycoside acetyltransferase gene, *aac(3)-Ib*, from *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 39:1790–1796.
51. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance *qnr* genes in ESBL-producing enterobacterial isolates. *J. Antimicrob. Chemother.* 60:394–397.
52. Noppe-Leclercq I, Wallet F, Haentjens S, Courcol R, Simonet M. 1999. PCR detection of aminoglycoside resistance genes: a rapid molecular typing method for *Acinetobacter baumannii*. *Res. Microbiol.* 150:317–322.
53. Datta N, Hughes VM. 1983. Plasmids of the same Inc groups in Enterobacteria before and after the medical use of antibiotics. *Nature* 306:616–617.
54. Johnson TJ, Bielak EM, Fortini D, Hansen LH, Hasman H, Debroy C, Nolan LK, Carattoli A. 2012. Expansion of the IncX plasmid family for improved identification and typing of novel plasmids in drug-resistant *Enterobacteriaceae*. *Plasmid* 68:43–50.
55. Norman A, Hansen LH, She Q, Sorensen SJ. 2008. Nucleotide sequence of pOLA52: a conjugative IncX1 plasmid from *Escherichia coli* which enables biofilm formation and multidrug efflux. *Plasmid* 60:59–74.
56. Palepou MF, Woodford N, Hope R, Colman M, Glover J, Kaufmann ME, Lafong C, Reynolds R, Livermore DM. 2005. Novel class A carbapenemase, KPC-4, in an *Enterobacter* isolate from Scotland, abstr 1134_1101_1120. Abstr. 15th Eur. Cong. Clin. Microbiol. Infect. Dis., Copenhagen, Denmark.
57. Robledo IE, Moland ES, Aquino EA, Vazquez GJ, Sante MI, Bertran J, Hanson ND. 2007. First report of a KPC-4 and CTX-M producing *K. pneumoniae* isolated from Puerto Rico (PR), abstr C2-1933. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
58. Robledo IE, Aquino EE, Sante MI, Santana JL, Otero DM, Leon CF, Vazquez GJ. 2010. Detection of KPC in *Acinetobacter* spp. in Puerto Rico. *Antimicrob. Agents Chemother.* 54:1354–1357.
59. Wolter DJ, Khalaf N, Robledo IE, Vazquez GJ, Sante MI, Aquino EE, Goering RV, Hanson ND. 2009. Surveillance of carbapenem-resistant *Pseudomonas aeruginosa* isolates from Puerto Rican medical center hospitals: dissemination of KPC and IMP-18 beta-lactamases. *Antimicrob. Agents Chemother.* 53:1660–1664.
60. Roth AL, Kurpiel PM, Lister PD, Hanson ND. 2011. *bla*_{KPC} RNA expression correlates with two transcriptional start sites but not always with gene copy number in four genera of Gram-negative pathogens. *Antimicrob. Agents Chemother.* 55:3936–3938.
61. Tardif G, Grant RB. 1983. Transfer of plasmids from *Escherichia coli* to *Pseudomonas aeruginosa*: characterization of a *Pseudomonas aeruginosa* mutant with enhanced recipient ability for enterobacterial plasmids. *Antimicrob. Agents Chemother.* 24:201–208.